Arthneeti
Latest: Nureca Q2 FY27 results →All Q2 FY26 results →
N

Nureca

Q2 FY26

Nureca Q2 FY26 investor presentation: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.

Price₹321
Market cap₹306 Cr
P/E70.5
Updated16 Oct 2026
Read3 min read

Based on Nureca's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Q2 FY26 EBITDA: INR 56 Mn, representing a 586% YoY growth (Q2 FY25 EBITDA was INR 8 Mn) - Q2 FY26 Profit After Tax (PAT): INR 36 Mn, a 10% YoY growth (Q2 FY25 PAT was INR -5 Mn, indicating a swing from loss to profit)

From Nureca's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25.
  • Q2 FY26 Sales: INR 377 million, a 21% YoY growth from INR 312 million in Q2 FY25.
  • H1 FY26 Revenue: INR 993 million.
  • H1 FY26 EBITDA: INR 76 million (10%).

2 more points from Nureca's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Nureca said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Q2FY26 capex reported at INR 4.2 million (Page 23)
  • Investment in in-house manufacturing focused on cutting-edge quality innovations to drive growth (Page 27)
  • Manufacturing capacity highlighted as 8 lakh units annually with new product launches and production capabilities in India (Page 8)

2 more points from Nureca's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Nureca said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Nureca said on order book & pipeline — free account, 30 seconds.

Nureca — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹59 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Nureca Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Aprameya Engineering Ltd (Q2 FY26)

    H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26

  • Tarsons Products Ltd (Q2 FY26)

    Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…

  • Vaidya Sane Ayurved Laboratories Ltd (Q2 FY26)

    Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…

  • Earkart Limited (Q2 FY26)

    Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt). Key concall takeaways from…

Compare:vs Poly Medicure Ltdvs Molbio Diagnostivs Sahajanand Medical Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Nureca and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Nureca Q2 FY26 results?

Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Q2 FY26 EBITDA: INR 56 Mn, representing a 586% YoY growth (Q2 FY25 EBITDA was INR 8 Mn) - Q2 FY26 Profit After Tax (PAT): INR 36 Mn, a 10% YoY growth (Q2 FY25 PAT was INR -5 Mn, indicating a swing from loss to profit)

What is Nureca share price analysis?

Nureca currently shows a neutral. The stock trades at a P/E of 70.5 with a market cap of ₹306 Cr. Investors should review the full earnings analysis for detailed insights.

Is Nureca planning capital expenditure?

Q2FY26 capex reported at INR 4.2 million (Page 23) - Investment in in-house manufacturing focused on cutting-edge quality innovations to drive growth (Page 27) - Manufacturing capacity highlighted as

Keep Nureca on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.